Trials / Completed
CompletedNCT05052567
CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1b/2 Clinical Study on Safety, Pharmacokinetics, and Preliminary Efficacy of CEND-1 for Injection in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the preliminary safety, efficacy and PK characteristics of cend-1 in patients with advanced metastatic pancreatic ductal adenocarcinoma (Chinese population).
Detailed description
This study is a multi-center, non-randomized, open-label phase Ib/II clinical study carried out in Chinese patients with advanced metastatic pancreatic ductal adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CEND-1 | The dose is specified according to the protocol. CEND-1+paclitaxel (albumin-bound type)+gemcitabine |
Timeline
- Start date
- 2021-10-21
- Primary completion
- 2024-06-29
- Completion
- 2024-06-29
- First posted
- 2021-09-22
- Last updated
- 2024-09-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05052567. Inclusion in this directory is not an endorsement.